{"id":1165,"date":"2016-12-30T17:46:16","date_gmt":"2016-12-30T17:46:16","guid":{"rendered":"http:\/\/depts.washington.edu\/diabetes\/?page_id=1165"},"modified":"2026-04-10T08:59:06","modified_gmt":"2026-04-10T15:59:06","slug":"opportunities-to-participate-in-clinical-research-2","status":"publish","type":"page","link":"https:\/\/depts.washington.edu\/diabetes\/opportunities-to-participate-in-clinical-research-2\/","title":{"rendered":"Opportunities to Participate in Clinical Research"},"content":{"rendered":"<p><section class=\"kc-elm kc-css-342610 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-161082 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-284860 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/grade.bsc.gwu.edu\/web\/grade\/home\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2021\/12\/DRG-Logo.png\" class=\"\" alt=\"VA Diabetes Research Group Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-693799 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/grade.bsc.gwu.edu\/web\/grade\/home\" class=\"kc_title_link\" title=\"\" target=\"\">The SURPASS-CVOT Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-823287 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>If you are living with type 2 diabetes, it\u2019s time to talk about your increased risk of cardiovascular events.\u00a0\u00a0<\/p>\n<p>Fortunately, the SURPASS-CVOT clinical research study is currently underway in your area.\u00a0 We are looking for volunteers to join SURPASS-CVOT, a clinical research trial that will test how effective an investigational study drug is when compared to dulaglutide (an approved diabetes medication) on major adverse cardiovascular events in people with type 2 diabetes mellitus (T2DM), and a history of cardiovascular disease (CVD).\u00a0<\/p>\n<p>Any trial-related investigational medications, laboratory tests and assessments that are over and above normal medical care will be provided at no cost to you. Reimbursement may also be available for trial-related expenses (such as travel).<\/p>\n<p>If you would like to know more, please contact us. We will be happy to answer any questions that you may have. We can also schedule an appointment so that you can learn about the study in detail and allow us to check whether you and the study are a good match.<\/p>\n<p><strong>Type of participant we are looking for:<\/strong><\/p>\n<ul>\n<li>Diagnosed with type 2 diabetes<\/li>\n<li>Be at least 40 years of age<\/li>\n<li>Have established cardiovascular disease (e.g. History of heart attack, stroke, vascular stents, bypass, peripheral artery disease)<\/li>\n<\/ul>\n<p><strong><a href=\"http:\/\/www.clinicaltrials.gov\">Clinicaltrials.gov<\/a> number<br \/><\/strong>NCT04255433<\/p>\n<p><b>Who to contact:<\/b><br \/>Karen Atkinson, Ellen Demmerle<br \/>Phone\u00a0number: 206-768-5338<b style=\"font-style: inherit;\">\u00a0<\/b><\/p>\n<p>\n<div class=\"kc-elm kc-css-897304\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-896648 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-731762\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-836471 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-962841 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-716122 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/benaroya-institute-header-logo.png\" class=\"\" alt=\"Benaroya Research Institute Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-896235 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" class=\"kc_title_link\" title=\"\" target=\"\">BRIDge study of Type 1 Diabetes at Benaroya Research Institute<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-340163 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>BRIDge is a research study to facilitate the understanding of diabetes and immune-mediated diseases. The study consists of a confidential registry where we store your contact, research, and health information, and a sample repository where we keep blood samples for current and future use in our research. The samples will be used for many different studies.<\/p>\n<p>An important part of this study is the sharing of information between researchers of different immune-mediated diseases. The samples and information obtained in this study are part of Benaroya Research Institute\u2019s Immune-Mediated Diseases Registry and Repository.<\/p>\n<p>We may contact you to see if you will come in for additional study visits or to update your health and contact information. We will always tell you what we need and let you decide if you are able to help us at that time. We may also contact you to let you know that you may be eligible for other studies.<\/p>\n<p><strong>Type of participant we are looking for:<\/strong><\/p>\n<ul>\n<li>Diagnosed with type 1 diabetes<\/li>\n<li>Relatives of people with type 1 diabetes<\/li>\n<li>Live in Seattle area<\/li>\n<\/ul>\n<p><strong><a href=\"http:\/\/www.clinicaltrials.gov\">Clinicaltrials.gov<\/a> number<br \/><\/strong>None<\/p>\n<p><b>Who to contact:<\/b><br \/>Outreach Team at Benaroya Research Institute<br \/>Phone number: 1-800-888-4187<br \/>Email address: <a href=\"mailto:diabetes@BenaroyaResearch.org\">diabetes@BenaroyaResearch.org<\/a><\/p>\n<p><strong>Website for more details about the study:<\/strong><br \/><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/clinical-research-vmfh\/bridge-study-type-1-diabetes\">BRIDGE Study of Type 1 Diabetes | Benaroya Research Institute<\/a>\u00a0<\/p>\n<p>\n<div class=\"kc-elm kc-css-403583\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-76517 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-754171\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-461949 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-912551 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-180687 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/benaroya-institute-header-logo.png\" class=\"\" alt=\"Benaroya Research Institute Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-83294 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" class=\"kc_title_link\" title=\"\" target=\"\">SAFEGUARD Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-469643 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.<\/p>\n<p><strong>Eligibility Criteria<\/strong><br \/>To be considered for this study you must be:<\/p>\n<ul>\n<li>Age 15 to 40 years old with a T1D diagnosis within the past three months.\u00a0<\/li>\n<\/ul>\n<p>Email: <a href=\"mailto:diabetes@benaroyaresearch.org\">diabetes@benaroyaresearch.org<\/a><br \/>Phone: 800-888-4187<\/p>\n<p>\n<div class=\"kc-elm kc-css-517634\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-90266 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-805146\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-914908 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-704587 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-891777 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/benaroya-institute-header-logo.png\" class=\"\" alt=\"Benaroya Research Institute Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-210797 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" class=\"kc_title_link\" title=\"\" target=\"\">BETA PRESERVE Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-995900 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>The BETA PRESERVE study will look at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them.\u00a0<\/p>\n<p><strong>Eligibility Criteria<\/strong><br \/>To be considered for this study you must be:<\/p>\n<ul>\n<li>Age 1 to 25 years old with a T1D diagnosis within the past month.\u00a0<\/li>\n<\/ul>\n<p>Email: <a href=\"mailto:diabetes@benaroyaresearch.org\">diabetes@benaroyaresearch.org<\/a><br \/>Phone: 800-888-4187<\/p>\n<p>\n<div class=\"kc-elm kc-css-640583\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-222915 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-185914\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-645836 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-463795 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-910304 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/benaroya-institute-header-logo.png\" class=\"\" alt=\"Benaroya Research Institute Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-940033 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" class=\"kc_title_link\" title=\"\" target=\"\">BETA PRESERVE Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-105531 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>The BETA PRESERVE study will look at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them.\u00a0<\/p>\n<p><strong>Eligibility Criteria<\/strong><br \/>To be considered for this study you must be:<\/p>\n<ul>\n<li>Age 1 to 25 years old with a T1D diagnosis within the past month.\u00a0<\/li>\n<\/ul>\n<p>Email: <a href=\"mailto:diabetes@benaroyaresearch.org\">diabetes@benaroyaresearch.org<\/a><br \/>Phone: 800-888-4187<\/p>\n<p>\n<div class=\"kc-elm kc-css-537541\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-510751 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-855715\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-569257 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-625391 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-893466 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/benaroya-institute-header-logo.png\" class=\"\" alt=\"Benaroya Research Institute Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-864419 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.benaroyaresearch.org\/our-research\/diabetes-clinical-research\/find-study\/bridge-study-of-t1d\" class=\"kc_title_link\" title=\"\" target=\"\">BRIAR Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-394335 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>The Benaroya Research Institute Autoimmune Registry (BRIAR) is a voluntary registry for individuals interested in participating in autoimmune disease research. Whether you live with an autoimmune condition, have a family member who does, or would like to be a healthy control volunteer, joining BRIAR helps advance scientific understanding and supports the development of future treatments.<\/p>\n<p>By enrolling, you will provide basic health information that helps us match you to current and future studies, and you will receive periodic research updates from Benaroya Research Institute (BRI). All the information you provide will be kept confidential and participation in future studies is always voluntary.<\/p>\n<p><strong>Eligibility Criteria<\/strong><\/p>\n<p>You are eligible to join BRIAR if you have any of the following:<\/p>\n<ul>\n<li>a personal history of one or more autoimmune\/immune-mediated condition(s)<\/li>\n<li>a healthy immune system, without any autoimmune\/immune-mediated conditions<\/li>\n<li>a family history of one or more autoimmune\/immune-mediated condition(s)<br \/>Parents or legal guardians may register on behalf of a child under age 18.<\/li>\n<\/ul>\n<p>Email: <a href=\"mailto:diabetes@benaroyaresearch.org\">diabetes@benaroyaresearch.org<\/a><br \/>Phone: 800-888-4187<\/p>\n<p>\n<div class=\"kc-elm kc-css-825060\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-996239 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-742168\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-277559 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-573793 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-167489 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.diabetestrialnet.org\/PathwayToPrevention\/index.htm\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/trial-net-logo.gif\" class=\"\" alt=\"Type 1 Diabetes Trial Net Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-532147 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.diabetestrialnet.org\/PathwayToPrevention\/index.htm\" class=\"kc_title_link\" title=\"\" target=\"\">Pathway to Prevention type 1 diabetes risk screening study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-463872 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet screens relatives of people with type 1 diabetes for their risk of developing the disease and can identify the early stages of T1D years before symptoms appear.\u00a0 The study also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.<\/p>\n<p>With a simple blood test TrialNet looks for diabetes-related autoantibodies. If autoantibodies are confirmed to be present, participants will be invited to join the monitoring part of the study and they may be eligible to participate in a prevention trial.<\/p>\n<p>Family members can order test kits to be mailed to them, free of charge, to collect a screening sample at home. To learn more or sign up, visit <a href=\"https:\/\/www.TrialNet.org\">https:\/\/www.TrialNet.org<\/a><\/p>\n<p><strong>Type of participant we are looking for:<\/strong><\/p>\n<ul>\n<li>Individuals 2 through 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)<\/li>\n<li>Individuals 2 through 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)<\/li>\n<\/ul>\n<p><strong><a href=\"http:\/\/www.clinicaltrials.gov\">Clinicaltrials.gov<\/a> number<br \/><\/strong>NCT00097292<\/p>\n<p><strong>Who to contact:<\/strong><br \/>Outreach Team at Benaroya Research Institute<br \/>Phone number: 1-800-888-4187<br \/>Email address: <a href=\"mailto:diabetes@BenaroyaResearch.org\">diabetes@BenaroyaResearch.org<\/a><\/p>\n<p><strong>Website for more details about the study:<\/strong><br \/><a href=\"https:\/\/www.trialnet.org\/\">https:\/\/www.TrialNet.org<\/a><\/p>\n<p>\n<div class=\"kc-elm kc-css-727291\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-96312 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-444604\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-109009 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-536544 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-689212 kc_shortcode kc_single_image\">\n\n        <a  href=\"https:\/\/www.diabetestrialnet.org\/PathwayToPrevention\/index.htm\" title=\"\" target=\"_self\">\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2016\/12\/trial-net-logo.gif\" class=\"\" alt=\"Type 1 Diabetes Trial Net Logo\" \/>    <\/a>\n    <\/div>\n\n<div class=\"kc-elm kc-css-41641 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\"><a href=\"https:\/\/www.diabetestrialnet.org\/PathwayToPrevention\/index.htm\" class=\"kc_title_link\" title=\"\" target=\"\">Rezpegaldesleukin for New Diagnosed T1D Study<\/a><\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-239345 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>TrialNet is studying rezpegaldesleukin to see if it can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance.<\/p>\n<p>Rezpegaldesleukin is already being studied in people with other autoimmune diseases like psoriasis and eczema. This is the first time it is being studied in people with TID.<\/p>\n<p>Like all clinical research, there are benefits and risks to participating in this study. Before you join the study, a TrialNet team member will explain all potential benefits and risks and answer your questions. For more details please visit: <a href=\"https:\/\/www.trialnet.org\/reset-t1d\">https:\/\/www.trialnet.org\/reset-t1d<\/a><\/p>\n<p><strong>Type of participant we are looking for:<\/strong><\/p>\n<ul>\n<li>Individuals 18 through 45 years old who have been newly diagnosed with type 1 diabetes and have screening tests showing: 1 or more diabetes-related autoantibody and detectable C-peptide during a mixed meal tolerance test (MMTT).<\/li>\n<\/ul>\n<p><strong>Who to contact:<\/strong><br \/>Outreach Team at Benaroya Research Institute<br \/>Phone number: 1-800-888-4187<br \/>Email address: <a href=\"mailto:diabetes@BenaroyaResearch.org\">diabetes@BenaroyaResearch.org<\/a><\/p>\n<p><strong>Website for more details about the study:<br \/><\/strong><a href=\"https:\/\/www.trialnet.org\/reset-t1d\">https:\/\/www.trialnet.org\/reset-t1d\u00a0<\/a><strong><br \/><\/strong><\/p>\n<p>\n<div class=\"kc-elm kc-css-130240\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-105552 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"sl-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-876477\" style=\"height: 14px; clear: both; width:100%;\"><\/div><section class=\"kc-elm kc-css-393950 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-587372 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-180444 kc_shortcode kc_single_image\">\n\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2020\/12\/Radiant-logo-300x90xc.png\" class=\"\" alt=\"RADIANT Logo\" \/>    <\/div>\n\n<div class=\"kc-elm kc-css-423591 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">RADIANT - Rare and Atypical Diabetes Network<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-449181 kc_text_block\"><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n<p>\nThe Rare and Atypical DIAbetes NeTwork (RADIANT) is dedicated to characterizing (discovering and defining) rare and atypical forms of diabetes.<\/p>\n<p>RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.<\/p>\n<p>RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).<\/p>\n<p><b>Type of participant we are looking for:<\/b><\/p>\n<ul>\n<li>Ages 0-80 with an atypical form of diabetes<\/li>\n<\/ul>\n<p><strong>Website for more details about the study:<\/strong><br \/><a href=\"https:\/\/www.atypicaldiabetesnetwork.org\/\">https:\/\/www.atypicaldiabetesnetwork.org\/<\/a><\/p>\n<p>\n<div class=\"kc-elm kc-css-761417\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-948296 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"et-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-352104\" style=\"height: 14px; clear: both; width:100%;\"><\/div><div class=\"kc-elm kc-css-195507 kc_shortcode kc_single_image\">\n\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2020\/12\/UWMDI-logo.png\" class=\"\" alt=\"UWMDI Logo\" \/>    <\/div>\n\n<div class=\"kc-elm kc-css-898513 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">DERMIS<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-45594 kc_text_block\"><\/div><\/p>\n<p>\nDERMIS is an investigational study looking to answer the questions of why pump wearers\u2019 skin changes after a number of years.<\/p>\n<p><b>Type of participant we are looking for:<\/b><\/p>\n<ul>\n<li>Type 1 adults over the age of 30, who are pump wearers either >20 years or &lt;10 years.<\/li>\n<\/ul>\n<p><b>Who to contact:<br \/><\/b>Dori Khakpour<br \/>Email address: <a style=\"background-color: #ffffff;\" href=\"mailto:dorik@uw.edu\">dorik@uw.edu<\/a><\/p>\n<p>\n<div class=\"kc-elm kc-css-755713\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-946311 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"et-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-361620\" style=\"height: 14px; clear: both; width:100%;\"><\/div><div class=\"kc-elm kc-css-973069 kc_shortcode kc_single_image\">\n\n        <img decoding=\"async\" src=\"https:\/\/depts.washington.edu\/diabetes\/wp-content\/uploads\/2020\/12\/UWMDI-logo.png\" class=\"\" alt=\"UWMDI Logo\" \/>    <\/div>\n\n<div class=\"kc-elm kc-css-111797 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">GLIDING<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-234603 kc_text_block\"><\/div><\/p>\n<p>\nGLIDING: A randomized comparison of transitioning from insulin GLargine to Insulin Degludec usING a bridging dose of glargine versus direct conversion, in patients with type 1 diabetes mellitus, is a small pilot study looking at two regimens (or treatment schedules) for people who switch from taking insulin glargine and insulin degludec.<\/p>\n<p>The main purpose of this study is to see if the participants switching with a bridging dose have less low blood sugars and better blood sugar control vs those who switch with no bridging dose. The results of this research may help design other or larger studies to look at better ways of switching insulins.<\/p>\n<p><b>Type of participant we are looking for:<\/b><\/p>\n<ul>\n<li>Patient who are type 1 and whose doctor wishes to change their insulin from Glargine to Degludec.<\/li>\n<\/ul>\n<p><b>Who to contact:<br \/><\/b>Thanmai Kaleru<br \/>Email address: <a href=\"mailto:tkaleru@uw.edu\">tkaleru@uw.edu<\/a><\/p>\n<p>\n<div class=\"kc-elm kc-css-334562\" style=\"height: 14px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-5419 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"et-notebook\"><\/i>\t<\/div>\n<\/div>\n<div class=\"kc-elm kc-css-925280\" style=\"height: 14px; clear: both; width:100%;\"><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false,"footnotes":""},"class_list":["post-1165","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/pages\/1165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/comments?post=1165"}],"version-history":[{"count":95,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/pages\/1165\/revisions"}],"predecessor-version":[{"id":14482,"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/pages\/1165\/revisions\/14482"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/diabetes\/wp-json\/wp\/v2\/media?parent=1165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}